AI second opinions for treating eye disease
Part of Cancer clinical trials.
This study tests whether showing doctors an AI-generated second opinion on retinal scans changes their treatment decisions for patients with a specific eye disease (nAMD, a common cause of vision loss). It aims to see if the AI helps doctors make better choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an ophthalmologist (eye doctor) or an eye doctor in training.
- You belong to one of the six doctor groups: non-retina specialist, resident, retina fellow, retina specialist, junior reader, or senior reader.
- You can spend about 30 minutes on this study.
- You have completed the necessary certification if you are a reader at an Image and Reading Center.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an AI system can help eye doctors write clearer and more accurate reports on retinal images (photos of the back of the eye). The focus is on how doctors and AI work together to describe eye findings.
This trial uses artificial intelligence to help diagnose eye conditions from digital eye images. If you have certain types of eye images from regular check-ups, your data might help teach the AI to recognise diseases better.
This trial tests how artificial intelligence can help doctors make better decisions about eye diseases. It may be a good fit if you have an eye condition and can share your medical records and images.
This study compares how well an artificial intelligence (AI) program decides on anti-VEGF eye injections versus a doctor's decision for conditions like wet macular degeneration, diabetic macular edema, and retinal vein occlusion. If you've already finished your initial loading doses, participating could help show whether AI can guide your future treatment.
This study tests whether a computer program (artificial intelligence) can use your eye scan images to help diagnose certain eye conditions. It might help catch problems earlier or more accurately, which could lead to better treatment.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.